Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.
Tadliq is a PDE5 inhibitor indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
Researchers studied the changes of pulmonary artery systolic pressure among patients with interstitial lung disease associated with systemic sclerosis receiving rituximab therapy.
The primary endpoint of the study was exercise capacity, as measured by the change from baseline in 6-minute walk distance at 24 weeks.
Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
Yutrepia is an inhaled dry powder formulation of tresprostinil delivered through a palm-sized device.
Tyvaso DPI is an investigational drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.
Absolute risk reduced by 19 percentage points, with number needed to treat to prevent syncope of 5.3
